25 Jun 2021 Alpine Immune Sciences Announces First Patient Dosed in Synergy, ALPN-101 Phase 2 Lupus Clinical Trial and $45 million in Development Milestones Achieved Under AbbVie Collaboration
25 Jun 2021 UCB Receives Positive CHMP Opinion Recommending Approval of BIMZELX[®*] (bimekizumab) in the EU for the Treatment of Adults with Moderate to Severe Plaque Psoriasis
25 Jun 2021 Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
25 Jun 2021 Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration
25 Jun 2021 Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ
24 Jun 2021 XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer
24 Jun 2021 Sintilimab in Combination with Chemotherapy Meets Overall Survival Primary Endpoint in the Global Phase 3 ORIENT-15 Study for the First-Line Treatment of Esophageal Squamous Cell Carcinoma
24 Jun 2021 Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease
24 Jun 2021 FDA Accepts Application for Genentech’s Port Delivery System With Ranibizumab (PDS) for Treatment of Wet Age-Related Macular Degeneration (AMD)
24 Jun 2021 Anti-TIGIT Domvanalimab-Based Combinations Showed Encouraging Clinical Activity in People with Metastatic, PDL1-High Non-Small Cell Lung Cancer at First Interim Analysis of Arcus Biosciences’ Randomized Phase 2 ARC-7 Study
23 Jun 2021 Alfasigma acquires the European license for bentracimab from PhaseBio
23 Jun 2021 DARZALEX® (daratumumab) Subcutaneous (SC) Formulation Becomes the First Approved Treatment for Newly Diagnosed Systemic Light Chain Amyloidosis in Europe and Gains an Additional Approval in Pre-Treated Multiple Myeloma
23 Jun 2021 ADC Therapeutics Announces Encouraging Interim Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) Presented at the 16th Annual International Conference on Malignant Lymphoma
22 Jun 2021 Augmenta Bioworks and TFF Pharmaceuticals Announce Selection of Lead Monoclonal Antibody Candidate AUG-3387 for Clinical Development Against COVID-19
22 Jun 2021 Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study and Announces Amended Loan Agreement with Oxford
22 Jun 2021 Nordic Nanovector Announces Initial Results from LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
22 Jun 2021 Prestige Biopharma’s First-in-Class Pancreatic Cancer Treatment, PBP1510, Receives Approval for Clinical Trial in France
22 Jun 2021 LEO Pharma announces European Commission approval of Adtralza® (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis
22 Jun 2021 Xentria Announces the Initiation of a Clinical Trial for XTMAB-16 for the Treatment of Sarcoidosis
22 Jun 2021 Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Patients With Persistent, Recurrent or Metastatic Cervical Cancer
22 Jun 2021 GSK and Vir Biotechnology announce continuing progress of the COMET clinical development programme for sotrovimab
18 Jun 2021 Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai’s MORAb-202 Antibody Drug Conjugate
17 Jun 2021 Amneal Announces U.S. FDA Filing Acceptance of Biologics License Application (BLA) for Bevacizumab
17 Jun 2021 Xilio Therapeutics Announces FDA Acceptance of IND Application for XTX101 for the Treatment of Solid Tumors
17 Jun 2021 BeiGene Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Cancer

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up